Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
ABSTRACT
BACKGROUND: Long-acting monoclonal antibodies (LAmAbs) could dramatically reduce the respiratory syncytial virus (RSV) disease burden in children if implemented using clear, evidence-based recommendations.
METHODS: The ARMADA Taskforce-an international, multidisciplinary expert panel-undertook a systematic review to develop LAmAbs consensus recommendations for RSV disease prevention in children.
RESULTS: The Taskforce recommends LAmAbs for all infants aged <8 months in the absence of maternal RSV vaccination, preterm infants (<37 weeks’ gestational age) aged <12 months, and children <24 months with high-risk conditions. Seasonal LAmAb administration is recommended, although in RSV-endemic countries decisions should be made locally concerning administration year-round or with peak RSV incidences.
CONCLUSIONS: The Taskforce strongly endorses LAmAbs implementation based on their efficacy, effectiveness, and public health impact. These recommendations provide a blueprint to inform guidelines worldwide. Wider equitable access to LAmAbs at affordable prices, especially in low- and middle-income countries is needed to reduce the childhood RSV burden.
PMID:40718547 | PMC:PMC12290402 | DOI:10.1093/ofid/ofaf396
